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The pleiotropic cytokine interferon alpha is involved in multiple aspects of lupus etiology and pathogenesis. Interferon alpha
is important under normal circumstances for antiviral responses and immune activation. However, heightened levels of serum
interferon alpha and expression of interferon response genes are common in lupus patients. Lupus-associated autoantibodies can
drive the production of interferon alpha and heightened levels of interferon interfere with immune regulation. Several genes in
the pathways leading to interferon production or signaling are associated with risk for lupus. Clinical and cellular manifestations
of excess interferon alpha in lupus combined with the genetic risk factors associated with interferon make this cytokine a rare
bridge between genetic risk and phenotypic eﬀects. Interferon alpha inﬂuences the clinical picture of lupus and may represent a
therapeutic target. This paper provides an overview of the cellular, genetic, and clinical aspects of interferon alpha in lupus.
1.Introduction
In systemic lupus erythematosus, a ﬁnely tuned system of
cells and signals is dysregulated, and the balance between
tolerance and autoimmunity is disrupted. Cytokines, as a
fundamental mechanism through which the immune system
is kept in balance, play an important role in the etiology and
pathogenesis of lupus. An example of an important cytokine
involved in lupus etiology and pathogenesis is interferon
alpha (IFNα).
IFNα is a pleiotropic cytokine that can aﬀect multiple
cell types involved in lupus. Several genes in the interferon
pathway are associated with risk for lupus, suggesting a role
for this pathway in etiology. Additionally, increased IFNα
levels and expression of IFN response genes are often found
in lupus. IFNα may aﬀect the clinical manifestations of lupus
and is a promising target for therapeutic interventions.
2.CellularAspectsof IFNαinLupus
Interferon alpha (IFNα) is a key molecule in immune
regulation. It is produced by multiple cell types in response
to viral infection. Plasmacytoid dendritic cells have a special
role in the production of IFNα and are the main sources of
serum interferon [1]. IFNα has the potential to dramatically
inﬂuence the development, progression, and pathogenesis of
SLE as it can inﬂuence the function and activation state of
most major immune cell subsets and function as a bridge
between innate and adaptive immunity.
2.1. Toll-Like Receptors and Interferon. One of the principal
mechanisms through which IFNα is produced is through
Toll-like receptor (TLR) signaling [2, 3]. TLR7 recognizes
single-stranded RNA, culminating in interferon regulatory
factor (IRF) 5 and IRF7 activation [4] and production of
IFN [5–7]. Excessive TLR 7 signaling produces lupus-like
autoimmunity in male Yaa mice, where an extra copy of the
TLR7 gene is present on the Y chromosome [8–10]. The
autoimmune phenotype conferred by the Yaa genotype is
dependent on IFN α, and addition of IFNα can partially
duplicatetheYaaphenotype[11].Additionally,knockingout
the IRF7 gene or inhibiting its action with pharmacologic
agents inhibits antibody production against RNA-containing2 Journal of Biomedicine and Biotechnology
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Figure 1: Putative source and eﬀects of interferon alpha in lupus.
RNA-containing complexes from apoptotic cells are bound by
autoantibodies. These immune complexes are internalized after
binding to FC receptors on plasmacytoid dendritic cells and
stimulate toll-like receptors in the endosomes. Toll-like receptor
ligation drives production of interferon alpha, leading to alteration
of T-cell proﬁles, disruption of regulatory T-cell networks, and
alteration of B-cell development.
nuclear components [12], suggesting that TLR7 is essential
for this type of autoantibody production.
Ac h a r a c t e r i s t i co fm a n yc a s e so fl u p u si st h ep r o d u c t i o n
of antibodies against RNA-containing protein complexes
such as Sm, nRNP, Ro, and La. In fact, antibodies against the
spliceosomal protein Sm are so speciﬁc for lupus that they
are used as a diagnostic criterion. The RNA found in these
complexes is capable of promoting the production of IFNα
through the stimulation of TLR7 [3, 13]( Figure 1).
Because TLR7 is located in the endosomes, RNA-
containing complexes must access the interior of the cell
before they are able to act as activators. Autoantibodies
speciﬁcfortheselupus-associatedriboproteinscanbindwith
antigens derived from apoptotic cells and form antibody-
protein-RNA complexes. The Fc portions of the immune
complexes are recognized and internalized by cells with Fc
receptors, providing a route of entry for RNA to reach TLR7,
resulting in interferon alpha production [3, 14]. This process
is especially well established in PDCs [15, 16]. Interestingly,
in addition to being produced as a result of TLR7 ligation,
IFNα enhances TLR7 signaling in PDCs [17, 18], forming a
positive feedback loop.
Despite these data and the strong association between
SLE-associated autoantibodies and serum IFNα,S L E -
associated autoantibodies are not suﬃcient for high serum
IFNα in humans in vivo [19]. Healthy subjects with anti-Ro
antibodies do not have high serum IFN-α, while a signiﬁcant
proportion of anti-Ro positive patients with SLE or Sjogren’s
syndrome do have high serum IFNα, suggesting that these
autoantibodies require other disease-associated factors to
result in high serum IFNα in humans.
2.2. IFNα and Adaptive Immune Regulation. Excess serum
IFNα and IFN-response gene expression are characteristics
of lupus and are most likely the result of excessive PDC
activation. Such high levels of interferon could contribute
to lupus by promoting immune activation rather than
tolerance.DendriticcellsaretheprimaryactivatorsofTcells,
and aﬀect both T-cell tolerance and activation, depending on
the state of the dendritic cell. When treated with interferon
alpha, dendritic cells mature and become more prone to
activate T cells [20, 21]. Myeloid dendritic cells from lupus
patients are able to phagocytose and present self-antigens to
T cells in a stimulatory, rather than regulatory manner, a
process which is interferon-dependent [22]. Such a process
likely contributes to loss of T-cell tolerance to self-antigens
and subsequent autoimmunity.
Exposure of the dendritic cell to IFNα contributes to
T cell polarity. When CD4+ T cells are activated in the
presence of IFNα-producing dendritic cells, their polarity
is shifted towards IFN-γ producing cells rather than IL-4
producing cells [23, 24], which may promote autoimmunity
or immune dysregulation. The T-cells activated by IFNα-
treateddendriticcellsalsoareenrichedforT-follicularhelper
cells, a recently described cell type which are adept at
activating B cells and driving antibody production [25].
Regulatory T cells (T-reg) are attracting increased atten-
tion as a mechanism of immune regulation and suppression
of autoimmunity. In lupus, T-regs are often, though not
always, found in lower numbers than in controls [26–
31]. Those T-regs that are present in lupus are ineﬃcient
at suppressing inﬂammation and T-cell proliferation [27,
29, 30, 32]. T-reg development is suppressed by treatment
of dendritic cells with IFNα [33]. In lupus patients, T-
reg activity is diminished, due at least in part to the
action of IFNα [34] indicating that increased IFNα levels in
lupus patients is likely contributing to the development or
maintenance of autoimmunity through suppression of T-reg
cells.
B cells are important in lupus, since humoral autoim-
munity is a hallmark of the disease. IFNα can prevent
apoptosis and enhance proliferation of primary B cells,
even in the absence of mitogenic stimuli [35]. Interestingly,
isolated B cells are inhibited from developing into antibody-
producing plasma cells by IFNα treatment [36]. However,
this inhibition is reversed if the B cells are allowed to come
into contact with monocytes, in which case IFNα actually
stimulates B-cell development and antibody production
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The ability of IFNα to inﬂuence the activation and func-
tion of many major immune cell subsets is a testament to the
wide and far-reaching eﬀects of this cytokine. It is clear that
interferon is dysregulated in lupus and that overexpression
of IFNα can result from the autoantibodies present in lupus.
Many components of the molecular pathways through which
IFNα and TLRs drive immune activation include genetic risk
factors for lupus, further implicating IFNα in lupus etiology
and pathogenesis.
3. IFN andIFN-Related Genes
AssociatedwithSLERisk
Lupus involves a combination of both environmental and
genetic factors. Support for a genetic component includes a
high sibling risk ratio [8–29], high heritability (greater than
66%), and higher concordance rates between monozygotic
twins (20 to 40%) as compared to other full siblings and
dizygotic twins (2 to 5%) [38, 39]. A large number of genetic
risk factors are associated with increased susceptibility to
the SLE. This genetically determined increased risk status
has been referred to as a “threshold liability” [40], which is
expected to be highly polygenic in nature and widely variable
between individuals. Environmental factors also aﬀect lupus
susceptibility and likely interact with this “threshold liabil-
ity”, but as in the case of genetic factors, there is no single
environmental cause. A person may have only a few of the
genetic risk variations and never get SLE despite exposure
to environmental triggers. In contrast, another person may
have many of these variations and then develop SLE on ﬁrst
exposure to an environmental trigger.
3.1. Lupus-Associated Risk Loci. Research into the etiopatho-
genesis of SLE has recently been advanced by several large
scale case-control genetic studies, including genome-wide
association scans. There is now a pool of approximately
30 genes that have been associated with SLE susceptibility
with a high degree of statistical certainty and many others
with probable evidence for association (reviewed in [41–
45]). With this large number of SLE-associated genes, we
can begin to group the list of identiﬁed SLE associated
genes which should provide insight into initial disease
pathogenesis into functional categories. These categories
include TLR and IFN signaling, apoptosis and clearance of
immune complexes, and B- and T-cell signaling. Several
genes aﬀecting the interferon pathway have been associated
with risk for lupus. The Interferon pathway normally serves
an important function in defense against viral infection.
Yet in people with genetic predisposition, environmental
triggers such as viral infections may tip the scales in favor
of autoimmunity.
Once a genetic variation is identiﬁed, functional infer-
ence then characterization is necessary to move from iden-
tiﬁcation to an understanding of how the variation aﬀects
the etiology or pathogenesis of SLE. Since most of the genes
involved in genetic susceptibility to SLE have been identiﬁed
only recently, there remains much work to identify the
functional diﬀerences in the genetic associations. However,
work done thus far in human cohorts is promising, and the
categories of genes and loci associated with risk of lupus
already suggest pathways that are of high importance.
3.2. Interferon Regulatory Factors. Certain lupus-associated
genetic variations have been shown to directly increase IFNα
levels or response to IFNα signaling. Interferon regulatory
factor 5 (IRF5) has been conﬁrmed as a risk locus in several
diﬀerent ethnic groups [46–50]. Three main functional
variantsinIRF5havebeendescribed,whichcombinetoform
a risk haplotype in individuals of European descent [51].
One of these loci, at rs2004640, creates an alternate splice site
(exon 1B) in the untranslated ﬁrst exon. Another is a copy
number variation of a 30-bp insertion/deletion sequence in
exon6,andtheﬁnalisrs10954213,whichcreatesanalternate
polyadenylation site, resulting in shorter, stabler mRNA
[52].
Since IRF5 activates IFNα production, these more stable
variants may pose a risk due to their ability to produce excess
IFNα. In fact, studies of this gene in human SLE cohorts
have shown that the risk variant predisposes to greater
serum IFN-α, supporting the idea that the risk haplotype
is a gain-of-function variant [53]. IRF5 itself is activated by
IFNαsignaling,producingapotentialpositivefeedbackloop.
Another IRF, IRF7, has been highlighted by the association
of the IRF7/KIAA1542 locus with lupus in recent studies
[54, 55]. Several SNPs in this area were shown to correlate
with IFNα levels and alter autoantibody proﬁles in certain
ethnicities [56].
IRF5 and IRF7 are activated by signaling through the
endosomal toll-like receptors (TLRs) 7, 8, and 9. Interest-
ingly, both of the IRF variants which are implicated in SLE
predispose to higher serum IFN-α, but only in the presence
of SLE-associated autoantibodies [53, 56] suggesting that
these autoantibodies may provide chronic stimulation of the
endosomal TLR pathway of IFN-α generation that when
combined with gain-of-function polymorphisms in the IRFs
results in dysregulation of the pathway in vivo. Additionally,
TLRs 8 and 9 were identiﬁed in recent studies as containing
susceptibility loci to SLE [57, 58]. The role of TLRs in the
interferon production was discussed above.
3.3. Interferon-Associated Genes. Another conﬁrmed locus
of susceptibility is in the gene encoding IL1 receptor-
associated kinase 1 (IRAK1). This kinase is part of the
signal transduction which follows TLR ligation. In a mouse
model of lupus, IRAK deﬁciency eliminated most lupus
symptoms, showing the importance of this key intermediate
[59]. Since this gene is on the X chromosome, gene dosage
may contribute to the risk and the prevalence of the disease
in women [59].
Two interacting proteins involved in inﬂammation,
TNFα-induced protein 3 (TNFAIP3) and TNFAIP3-inter-
acting protein 1 (TNIP1), have been identiﬁed as risk loci
[60–64]. TNFAIP3 encodes the protein A20, which helps
turn oﬀ signaling through NFκB after an inﬂammatory
response [65, 66]. TNIP1 interacts with TNFAIP3 and is
involved in several signal transduction pathways.4 Journal of Biomedicine and Biotechnology
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Figure 2: Multiple genes involved in interferon production and
regulationareassociatedwithriskforlupus.Shownarecomponents
of the signal transduction pathway from TLR stimulation by
nucleic acids to IFN production. Genes that have been associated
with risk for lupus are marked (∗). IFN: interferon, IRAK:
interleukin-1 receptor-associated kinase, IRF: interferon regulatory
factor, MyD88: myeloid diﬀerentiation primary response gene 88,
OPN: osteopontin, pDC: plasmacytoid dendritic cell, TLR: toll-like
receptor, TNFAIP3: tumor necrosis factor alpha induced protein 3,
TNIP1: TNFAIP3 interacting protein 1, and TRAF6: tumor necrosis
factor receptor-associated factor 6.
Signal transducer and activator of transcription 4
(STAT4) is another risk locus with direct links to the inter-
feron pathway. It is involved in proliferation, diﬀerentiation,
and apoptosis. STAT4 has 2 risk loci, one at rs7574865 which
has been shown to increase sensitivity to IFNα [67], and
another at rs3821236 which increases STAT4 transcription
and interacts with IRF5 susceptibility loci [68]. The presence
of both of these risk alleles gives an additive eﬀect, increasing
risk to SLE [69]. Osteopontin (OPN) is a key molecule for
IFNα production in pDCs [70]. Presence of a lupus risk-
associated form of this gene was recently tied to high IFN
levels in males and young-onset female lupus patients [71].
Possible interactions of the IFN-associated genes that
have been linked to lupus are shown in Figure 2. The risk
variants of these genes inﬂuence the production of and
response to IFNα, likely driving the increased levels seen in
lupus patients and aﬀecting the clinical manifestations of the
disease.
4.ClinicalAspects of IFNαinLupus
Lupus primarily aﬀects women in the reproductive years;
however people of all ages, genders, and ancestral back-
grounds are susceptible. Disease features range from mild
manifestations such as rash or arthritis to life-threatening
end-organ manifestations such as glomerulonephritis or
thrombosis,anditisdiﬃculttopredictwhichmanifestations
will aﬀect a given patient.
4.1. IFN-α as a Causal Factor in Human Lupus. An u m -
ber of patients treated with IFNα have developed lupus
or lupus-like syndrome [72–74]. In these reports, many
speciﬁc manifestations of idiopathic lupus such as malar or
discoid rash, oral ulcers, photosensitivity, renal involvement,
and anti-Sm and anti-dsDNA antibodies were represented,
suggesting that these cases were not “drug-induced” SLE but
instead resembled idiopathic SLE [73]. Discontinuation of
IFNα typically resulted in remission of SLE symptoms [73],
supporting a causal relationship with IFN-α. While only a
minority of patients treated with IFNα develop SLE (<1%
of patients) [75], these data support the idea that IFNα can
be suﬃcient to induce SLE in some individuals. Many more
IFNα-treated individuals develop a “lupus-like” syndrome
[74], with some SLE symptoms which are insuﬃcient to
meet formal diagnostic criteria for SLE [76]. IFN-induced
SLE can be severe, and there are reports of life-threatening
multiorgan SLE involvement including glomerulonephri-
tis, serositis, discoid rash, myopericarditis, and vasculitis
[77, 78].
Another ﬁnding which supports the hypothesis of IFNα
as a primary causal factor in human SLE is the clustering
of high serum IFNα in lupus families [79]. Patients with
lupus and their healthy relatives have higher serum IFNα
activity as compared to healthy unrelated individuals [79].
Strong familial correlations in serum IFNα were observed
regardlessofdiseasestatus(aﬀectedsversusunaﬀecteds),and
SLEprobandsinthesamefamilytendedtohavesimilarIFNα
levels [79]. Spouses of SLE patients did not have high serum
IFNα activity, and taken together these data suggest that high
serum IFNα is a heritable risk factor for SLE. Interestingly,
age-relatedpatternsofserumIFNαwerealsoobservedinSLE
families in which the ages of highest IFNα mirrored the ages
ofpeakSLEincidence[80,81]. The discovery of several lupus
risklociinIFN-relatedgenesprovidesfurthersupportforthe
aboveobservationthatserumIFN-αisheritable,andtheSLE
riskvariantsofeachofthesegenesresultinagainoffunction
increase in IFNα signaling as detailed above.
4.2. Clinical Correlations with IFN Alpha. Av e r ys t r o n g
correlation is consistently observed between the presence
of SLE-associated autoantibodies, such as anti-Ro, anti-La,
anti-Sm, anti-RNP, and anti-dsDNA [79, 82]. Lupus patients
with high serum IFNα had a signiﬁcantly higher prevalence
of cutaneous and renal disease in most studies [82–84]. It
is interesting that both of these clinical manifestations share
an association with a particular serology (rash with anti-Ro
and nephritis with anti-dsDNA), and whether these clinical
manifestations are associated independent of serology has
not been shown to our knowledge.
A number of studies have shown that IFNα correlates
with disease activity when assessed cross sectionally [82–85].
Results are conﬂicting regarding the potential ﬂuctuation of
IFNα with disease activity in SLE, and there are a number
of studies which did not ﬁnd a longitudinal correlation [86,
87]. In these studies, a cross-sectional relationship between
IFNα and disease activity is still observed, suggesting that
IFNα may indicate those patients who generally have higherJournal of Biomedicine and Biotechnology 5
disease activity as compared to other patients. A recent
prospective study evaluated the utility of serum interferon-
regulated chemokine levels as potential biomarkers of SLE
diseaseactivity[88].Inthisstudy,IFNα-inducedchemokines
correlated with disease activity cross sectionally, rose at the
time of a ﬂare, and decreased as the disease remitted [88]. In
thissamestudy,highchemokinelevelswerepredictiveofSLE
ﬂare over the next year in a subset of patients.
4.3. Anti-IFNα Therapies in Lupus. Given all of the studies
presented above, there has been considerable interest in
therapies which block IFNα. To date there is one published
study describing a phase I trial of a fully human monoclonal
antibody that binds to the majority of the subtypes of
human interferon alpha [89]. Treatment with this anti-
IFN antibody resulted in a dose-dependent inhibition of
interferon-induced gene expression in peripheral blood cells
as well as skin lesions in patients with mild to moderate
SLE [89]. No obvious safety signals were reported during
the phase I trial of anti-IFN therapy, and the proof-of-
principle analyses supported a biological eﬀect blocking the
IFN pathway in humans. Phase two trials to assess eﬃcacy
of these agents in treating SLE are currently underway.
There are many known predictors of high serum IFNα in
SLE patients, including both serologic and genetic markers
outlined in this paper. We anticipate that incorporation
of these variables into clinical trial design would enhance
eﬃcacy and potentially minimize side eﬀects by targeting
the most relevant patient group. Long-term safety data will
be important, since IFNα is such a highly conserved and
important immunological mediator of viral defense.
5. Conclusions
IFN-α is associated with SLE through multiple lines of
evidence. These include genetic, immunological/serological,
and clinical associations, as described in this review. It
is likely that IFN-α p l a y sak e yr o l ei nS L Ee t i o l o g y ,
pathogenesis, and/or disease persistence. Despite this large
body of evidence associating IFN-alpha with lupus, the
association between interferon alpha and SLE is largely infer-
ential. The exact cellular and immunological mechanisms
through which IFN aﬀects lupus also remain undiscovered
for the most part. These mechanisms and pathways are
potentially fertile areas for future investigation. Such studies
will likely lead to new therapeutic targets as well as a greater
understanding of lupus as a disease.
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